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ABSTRACT
Objectives: The aim of the study was to determine maternal serum total antioxidant status (TAS), total oxidant status 
(TOS), oxidative stress index (OSI), paraoxonase (PON) and arylesterase levels in severe preeclamptic pregnants and also 
to investigate whether these parameters are implicated in the occurence of perinatal morbidity or not.
Material and methods: A case-control study was carried out including 60 pregnant women (30 with severe preeclampsia 
and 30 healthy controls). The optimal cut off points of oxidative stress markers for the diagnosis of severe preeclampsia and 
for the prediction of adverse perinatal outcomes were evaluated by receiver operating characteristic (ROC) analyses. Multi-
variate logistic regression analysis was used to determine if a relationship between adverse perinatal outcomes and serum 
oxidative stress markers was present or not.
Results: TAS (OR = 37.486, 95% CI 3.535–397.519, p = 0.003), TOS (OR = 15.588, 95% CI 2.135–113.818, p = 0.007) and ary-
lesterase (OR = 31.356, 95% CI 2.284–430.548, p = 0.01) were found to be diagnostic for preeclampsia. Statistically significant 
positive correlation of adverse perinatal outcomes with serum TAS, PON and arylesterase levels were determined. Besides, 
a significant negative correlation was found between serum TAS levels and gestational week (r = –0.342, p = 0.007) and 
also between serum PON levels and birthweight (r = –0.262, p = 0.043).
Conclusions: Increased maternal serum TAS, TOS and arylesterase levels are significantly associated with the presence of 
severe preeclampsia. Furthermore, elevated maternal serum TAS, PON and arylesterase levels are significantly and positively 
correlated with adverse perinatal outcomes. We suggest that in preeclampsia increased oxidative status may cause adverse 
perinatal outcomes and antioxidants may be increased in order to protect the fetus against oxidative damage.
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INTRODUCTION
Preeclampsia is a catastrophic, pregnancy-specific dis-
order, affecting 5–10% of all pregnancies and the leading 
cause of adverse pregnancy outcomes [1]. Diverse factors 
have been suggested to play a role in the etiopathogenesis 
of preeclampsia, including endothelial cell injury, impaired 
placentation and angiogenesis, changes in local oxygen 
tension, genetic predisposition, and immunological altera-
tions [2–6]. Although the exact underlying mechanism is still 
obscure, it seems that maternal immune maladaptation is 
the triggering factor leading to inadequate placentation 
and altered endothelial function [7, 8]. Endothelial dys-
function results in increased systemic vascular resistance, 
leading to reduced perfusion in maternal systems, including 
the placenta [9]. Reduced perfusion aggravates placen-
tal ischemia-reperfusion injury, which is a strong stimulus 
for the production of reactive oxygen species (ROS) [10]. 
Additionally, increased generation of ROS, increased lipid 
peroxidation, and/or decreased antioxidant status further 
exacerbate endothelial dysfunction [11].
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Increased oxidative stress has been already demon-
strated to contribute in many cardiovascular diseases [12]. 
The characteristic vascular lesions in preeclampsia were 
shown to be similar to atherosclerotic plaques with lipid 
accumulation and infiltration of foam cells. Thus, it has been 
proposed that the changes in preeclampsia may be medi-
ated by abnormal lipid peroxidation [13,14]. Lipid peroxida-
tion causes cellular damage and vascular endothelial cell 
injury, and is used as an indicator of oxidative stress [15]. 
Oxidized LDL-cholesterol particles were also previously 
suggested to be involved in vascular endothelial injury in 
preeclampsia [16].
Paraoxonase (PON), is an antioxidant enzyme which is 
bound to HDL-cholesterol and has been shown to contrib-
ute in the prevention of LDL and HDL peroxidation [17]. 
PON has both, paraoxonase and arylesterase activity since 
it hydrolyzes organophosphates and aromatic esters [18]. 
Paraoxonase activity and oxidative status have been already 
shown to be altered in endothelial dysfunction-related dis-
orders such as diabetes and cardiovascular diseases [19, 20]. 
Similarly, one of the major and probably the causal problems 
in preeclampsia is endothelial dysfunction, so it may be 
proper to suggest an imbalance in oxidant and antioxidant 
status in the pathophysiology of preeclampsia. However, 
previous studies reported conflicting results of maternal 
serum PON and arylesterase levels in preeclampsia [15, 21]. 
Furthermore, the reported total oxidant status (TOS), total 
antioxidant status (TAS), and oxidative stress index (OSI) 
values were also controversial in different studies [10, 22]. 
Considering the results of the above-mentioned studies, we 
hypothesized that since preeclampsia and atherosclerotic 
diseases share a common pathophysiological mechanism, 
namely endothelial dysfunction, it may cause alterations in 
the perfusion of the utero-placental-fetal unit and lead to 
adverse perinatal outcomes.
OBJECTIVES
In our study, we aimed to determine maternal serum 
TAS, TOS, OSI, PON and arylesterase levels in severely preec-
lamptic pregnant patients and also to investigate whether 
these parameters were implicated in the occurrence of 
preeclampsia-related perinatal morbidity.
MATERIAL AND METHODS
A prospective case-control study was carried out be-
tween September 2013 and January 2014. Thirty patients 
diagnosed with preeclampsia were consecutively recruited 
from the Obstetrics and Gynecology Department, Zekai 
Tahir Burak Women’s Health Education and Research Hos-
pital. Severe preeclampsia was defined as blood pressure 
of ≥ 160 mm Hg systolic or ≥ 110 mmHg diastolic which 
occurs after 20 weeks of gestation in previously normoten-
sive women, with proteinuria as urinary excretion of ≥ 0.3 g 
protein in a 24-hour urine specimen. In the absence of pro-
teinuria, preeclampsia was defined as hypertension associ-
ated with at least one of the following: thrombocytopenia 
(platelet count of < 100,000 /µL), impaired liver function (in-
crease in serum transaminases to twice the normal concen-
tration), renal insufficiency (serum creatinine of > 1.1 mg/dL 
or doubling of serum creatinine in the absence of other renal 
diseases), pulmonary edema, and new-onset cerebral or 
visual disturbances [23]. The exclusion criteria were: multiple 
pregnancy, type I or II diabetes mellitus, chronic hyperten-
sion, hyper/hypothyroidism, chronic liver or renal disease, 
vascular and inflammatory diseases, smoking, and fetal 
anomaly. Thirty age- and BMI-matched healthy, pregnant 
women were recruited as controls.
All participants were evaluated at the initial admission. 
Clinical and anthropometric data were recorded. Gestational 
age was confirmed in all pregnant women by a routine 
ultrasonographic examination performed during the first 
trimester. Blood samples were obtained at the time of di-
agnosis, following overnight fasting, and processed within 
1h after withdrawal by centrifugation, and stored at –80ºC 
until the day of the analysis. The adverse perinatal outcomes 
investigated in our study were as follows: low birthweight, 
preterm delivery, admission to a neonatal unit, and intra-
uterine growth retardation.
Serum TOS levels were determined spectrophotometri-
cally using a method previously described by Erel, and the 
results were expressed in terms of micromolar hydrogen 
peroxide equivalent per liter (µmol H2O2 eqv./L) [24]. Serum 
TAS levels were determined using a novel method previously 
described by Erel, and the results were expressed as mili-
molar trolox equivalent per liter (mmol Trolox eqv./L) [25]. 
The ratio of TAS to TOS represents the OSI, an indicator of 
the degree of oxidative stress. Paraoxonase and arylesterase 
activities were measured using commercially available kits 
(RelassayR, Gaziantep, Turkey). 
All participants provided a written informed consent. 
The study protocol was designed according to the principles 
of the Declaration of Helsinki and approved by the Local 
Ethics Committee. 
BM SPSS Statistics for Windows, Version 20.0 (Armonk, 
NY: IBM Corp.) was used for statistical analysis. Continu-
ous variables were tested for normality with the Kol-
mogorov–Smirnov test. Normally distributed data are pre-
sented as mean ± standard deviations. Categorical com-
parisons were performed using the Chi-Square Test. For 
non-normally distributed data, median with data range 
(minimum to maximum) was used. We used the indepen-
dent samples t-test and Mann-Whitney U test for parametric 
and nonparametric groups, respectively. The optimal cut-off 
points of laboratory parameters determining preeclampsia 
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were evaluated by ROC analyses calculating the area under 
the curve as giving the maximum sum of sensitivity and 
specificity for the significant test. Sensitivity and specific-
ity were also calculated at the best cut-off point for each 
clinical measurement. In order to determine whether oxi-
dative stress markers were independently associated with 
the presence of preeclampsia, multiple logistic regression 
analysis was used. Odds ratios and 95% confidence intervals 
for each independent variable were also calculated. The 
p-value of < 0.05 was considered as statistically significant. 
Multivariate logistic regression analysis was also used to 
determine the presence of a relationship between adverse 
perinatal outcomes and serum oxidative stress markers. The 
p-value of < 0.05 was considered as statistically significant.
RESULTS
Sixty pregnant women were enrolled in the study: 
30 preeclamptic patients and 30 age- and BMI-matched 
healthy pregnant controls. The baseline characteristics of 
preeclamptic patients and controls are presented in Table 1. 
There were no statistically significant differences with re-
spect to age, BMI, weight gain in pregnancy and gravid-
ity between the groups. The percentage of adverse fetal 
outcomes and cesarean sections was significantly higher 
in the group with preeclampsia. Maternal serum TAS, TOS, 
PON, arylesterase levels and OSI were significantly higher in 
the preeclamptic group as compared to controls (Table 1).
Serum TAS, TOS, PON, arylesterase and OSI levels were 
again evaluated with ROC analysis, cut-off levels were de-
termined, and the areas under curve (AUC) were calculated 
(Figure 1). The AUC, best cut-off values, sensitivity and speci-
ficity for distinguishing the groups for each parameter are 
presented in Table 2. All parameters except for OSI were 
found to be statistically significant. Multivariate logistic 
regression analysis was then used to determine the pres-
ence of a relationship between the groups and the defined 
cut-off levels of the laboratory parameters. TAS (OR = 37.486, 
95% CI 3.535–397.519, p = 0.003), TOS (OR = 15.588, 95% 
CI 2.135–113.818, p = 0.007) and arylesterase (OR = 31.356, 
95% CI 2.284–430.548, p = 0.01) were found to be indicative 
of preeclampsia (Table 3). Also, according to the results of 
the logistic regression model comparing the risk factors in 
patients with preeclampsia, the diagnostic performance 
of TAS, TOS, PON and arylesterase together was estimated 
at 90%.
Further analysis was also performed to determine the 
presence of a correlation between oxidative stress markers 
and different variables in all pregnant participants of the 
study (Table 4). Statistically significant positive correlations 
between adverse perinatal outcomes and serum TAS, PON 
and arylesterase levels were determined. Besides, a sig-
nificant negative correlation was found between serum 
TAS levels and gestational week (r = –0.342, p = 0.007) and 
also between serum PON levels and birthweight (r = –0.262, 
p = 0.043). Multivariate logistic regression analysis, used to 
determine the predictive value of defined cut-off levels of 
the laboratory parameters and adverse perinatal outcomes, 
failed to determine such an association (p > 0.05).
DISCUSSION
In our prospective case-control study, the elevated levels 
of maternal serum TAS, TOS and arylesterase levels were 
Table 1. Baseline characteristics and laboratory parameters of preeclamptic patients and controls
Preeclampsia group (n = 30) Control group (n = 30) P value*
Age (years) 31.6 ± 5.4 31.5 ± 5.7 0.982
BMI [kg/m2] 30.4 ± 4.2 29.9 ± 3.9 0.588
Weight gain [kg] 13.0 ± 4.4 12.1 ± 6.3 0.493
Gravidity (n) 2.0 ± 2.0 3.0 ± 1.0 0.214
Gestational weeks 34.2 ± 3.6 38.5 ± 1.3 < 0.001
Fetal weight [g] 2173.7 ± 965.9 3167.3 ± 493.3 < 0.001
Adverse perinatal outcome [n (%)] 18 (60%) 0/30 (100) < 0.001
Route of delivery 
Cesarean/vaginal [n (%)]
 
28 (93.3)/2 (6.7)
 
13 (43.3)/17 (56.7)
 
< 0.001
TAS [mmol/mL] 2.1 ± 0.4 1.6 ± 0.2 < 0.001
TOS 9.5 ± 5.1 5.6 ± 1.7 < 0.001
PON 244.9 ± 83.6 191.1 ± 56.5 0.005
ARES 309.5 ± 84.0 216.8 ± 49.4 < 0.001
OSI 4.6 ± 2.5 3.5 ± 1.1 0.027
Independent T Test – Mann-Whitney U test (Exact) – Pearson Chi-Square Test (Exact) & Fisher Exact Test (Exact). Data are presented as Mean ± SD (standard deviation)
[*median ± IQR (inter quartile range); **n (%)]; BMI — body mass index; OSI — oxidative stress index
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found to be associated with severe preeclampsia. Addition-
ally, elevated maternal serum TAS, PON and arylesterase lev-
els were significantly and positively correlated with adverse 
perinatal outcomes.
Oxidative stress has been already suggested to play 
an important role in the pathogenesis of placenta-related 
diseases [26]. Various studies showed increased oxidant 
status in preeclamptic pregnancies and suggested that oxi-
dative stress is a major contributor in preeclampsia-related 
endothelial dysfunction [10, 22, 27]. Our findings are consist-
ent with the results of previous studies as we found elevated 
levels of maternal serum TOS to be associated with severe 
Table 2. Cut-off values for laboratory parameters of preeclamptic patients and controls 
Cut-off value
Group
P valueStudy (n = 30) Control (n = 30)
n (%) n (%)
TAS
< 1.7225/1.7225 ≤ 3 (10)/27 (90) 19 (63.3)/11 (36.7)
< 0.001
0.859 ± 0.46*** (90.0%)*/(63.3%)**
TOS
< 6.95/6.95 ≤ 11 (36.7)/19 (63.3) 24 (80)/6 (20)
< 0.001
0.793 ± 0.056*** (63.3%)*/(80.0%)**
PON
< 216/216 ≤ 12 (40)/18 (60) 22 (73.3)/8 (26.7)
0.007
0.702 ± 0.068*** (60.0%)*/(73.3%)**
ARES
< 299.15/299.15 ≤ 16 (53.3)/14 (46.7) 30 (100)/0 (0)
< 0.001
0.809 ± 0.055*** (53.3%)*/(100%)**
OSI
≤ 3.1395/3.1395 < 9 (30)/21 (70) 15 (50)/15 (50)
0.128
0.614 ± 0.073*** (70.0%)*/(50.0%)**
TAS — total antioxidant status; TOS — total oxidant status; PON — paraoxonase; OSI — oxidative stress index
Table 3. Logistic regression model comparing the risk factors in patients with preeclampsia
B S.E. Wald P OR 95% CI
TAS ≥ 1.7225 3.624 1.205 9.049 0.003 37.486 3.535–397.519
TOS ≥ 6.95 2.747 1.014 7.331 0.007 15.588 2.135–113.818
PON ≥ 216 1.633 0.996 2.686 0.101 5.118 0.726–36.070
ARES ≥ 292.2 3.445 1.337 6.645 0.010 31.356 2.284–430.548
Constant –4.999 1.430 12.226 0.000 0.007
OR — odds ratio; CI — confidence interval; TAS — total antioxidant status; TOS — total oxidant status; PON — paraoxonase; OSI — oxidative stress index
Table 4. Correlation analysis between oxidative stress markers and different variables in all participants
Age BMI GW Gravida EFW WG TAS TOS PON ARES APO OSI
TAS
r 0.016 –0.022 –0.342 –0.181 –0.251 –0.024 1 0,344 0,128 0,528 0.403 –0.005
p 0.905 0.867 0.007 0.166 0.054 0.853 0.007 0.329 0.000 0.001 0.971
TOS
r 0.214 0.096 –0.177 0.047 –0.115 –0.015 0.344 1 0.264 0.123 0.238 0.925
p 0.100 0.467 0.177 0.720 0.381 0.911 0.007 – 0.041 0.348 0.067 0.000
PON
r –0.026 0.033 –0.173 0.011 –0.262 –0.081 0.128 0.264 1 0.302 0.276 0.258
p 0.845 0.805 0.187 0.934 0.043 0.540 0.329 0.041 – 0.019 0.033 0.047
ARES
r –0.063 0.148 –0.235 –0.144 –0.224 0.062 0.528 0.123 0.302 1 0.257 –0.015
p 0.635 0.258 0.070 0.272 0.086 0.641 0.000 0.348 0.019 – 0.047 0.907
OSI
r 0.237 0.124 –0.050 0.155 –0.014 –0.012 –0.005 0.925 0.258 –0.015 0.095 1
p 0.068 0.344 0.703 0.236 0.917 0.925 0.971 0.000 0.047 0.907 0.468 –
BMI — body mass index; TAS — total antioxidant status; TOS — total oxidant status; PON — paraoxonase; OSI — oxidative stress index
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preeclampsia. Although increased oxidative stress is already 
accepted to be implicated in preeclampsia, either as a patho-
genetic mechanism or as a consequence, the controversy 
about the possible roles of antioxidant status and enzyme 
levels remains [28]. A number of studies reported decreased 
TAS levels as a reduction in antioxidant defense mechanisms 
in preeclampsia [22, 27, 29]. These studies are contradictory 
to our results since we found significantly increased levels 
of TAS in severely preeclamptic patients. However, the find-
ings of two studies are consistent with our results, as they 
reported significantly increased TAS levels in maternal serum 
and cord blood of the newborns in preeclampsia [10, 30]. 
Additionally, there are also conflicting data among serum 
PON and arylesterase levels in preeclampsia. Kumru et al., 
reported significantly lower levels of PON and arylesterase 
in severe preeclampsia [21]. Conversely, Sarandol et al., 
showed that serum PON and arylesterase activities were 
not different in both, mild and severely preeclamptic pa-
tients [31]. We found significantly increased levels of PON 
and arylesterase and a positive correlation between both 
antioxidant enzymes with adverse perinatal outcomes in 
severe preeclampsia. Similarly, Acıkgoz et al., reported in-
creased PON activity in preeclampsia [32]. Furthermore, 
Altunhan et al., found increased PON activity in cord blood of 
the newborns born to preeclamptic mothers and suggested 
that increased cord blood TAS and PON levels indicate that 
the fetus is protected against oxidative damage [30]. Their 
results are consistent with our study, as we found a posi-
tive correlation between adverse perinatal outcomes and 
increased antioxidant mechanisms. Although regression 
analysis failed to show a significant relation, we suggest 
that protection against oxidative stress may be higher in 
preeclamptic mothers, with a probable adverse pregnancy 
outcome since a significant positive correlation was deter-
mined. Another explanation for the statistically insignificant 
results may be the small size of the groups. 
The main limitation of our study was a relatively small 
size of the groups. Although there was an evident correlation 
between serum TAS, PON, arylesterase levels and adverse 
perinatal outcomes, it missed the level of statistical signifi-
cance due to the small sample size. Thus, this study needs 
to be validated with larger cohorts.
CONCLUSIONS
Increased maternal serum TAS, TOS and arylesterase lev-
els are significantly associated with the presence of severe 
preeclampsia. Furthermore, elevated maternal serum TAS, 
PON and arylesterase levels are significantly and positively 
correlated with adverse perinatal outcomes. As increased 
activity of TAS, PON and arylesterase shows the second-
ary activation of defense mechanisms, we suggest that in 
preeclampsia increased oxidative status may cause adverse 
perinatal outcomes and antioxidants may be increased in 
order to protect the fetus against the oxidative damage.
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